Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Sümbol: 300357.SZ

SHZ

25.97

CNY

Turuhind täna

44.2441
P/E suhe
-6.3048
PEG suhe
13.60B
MRK Cap
0.01%
DIV tootlus

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010
balance-sheet.row.cash-and-short-term-investments	1288.8	1135.7	1020.9	890.7	792.1	460	185.8	235.5	271.8	275.5	103.3	64.1	42	27.4	43.5
balance-sheet.row.short-term-investments	117.4	295.1	370.9	307	41.4	13	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	214.9	284.9	256.2	220.5	211	179.2	149.5	117.9	103.3	99.5	85.3	66.6	49.3	27.6	19.2
balance-sheet.row.inventory	59	48.4	53.8	48.3	36.8	23.5	19.8	14	9.2	11.9	8	5	4.6	3.6	3.8
balance-sheet.row.other-current-assets	7.2	8.1	10.7	11.4	10	119	301.4	171.8	100	60	-1.5	-0.9	-1	-0.6	9
balance-sheet.row.total-current-assets	1569.9	1477.1	1341.5	1170.9	1050	781.7	656.5	539.2	484.3	446.9	195.1	134.8	95	57.9	75.5
balance-sheet.row.property-plant-equipment-net	704.8	444.6	301.6	240.2	197.6	137.7	123.6	118.5	97	60.3	48.4	38.7	36.6	38.6	32.3
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	188.4	189.5	176.4	170.4	160.9	123.4	53.1	36.8	27.8	21.8	19.4	16.2	14.6	13.2	12.5
balance-sheet.row.goodwill-and-intangible-assets	188.4	189.5	176.4	170.4	160.9	123.4	53.1	36.8	27.8	21.8	19.4	16.2	14.6	13.2	12.5
balance-sheet.row.long-term-investments	-43.2	-216.7	-287.6	-293.2	-28.2	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	5	4.9	5.8	4.9	3.7	1.9	1.7	1.7	1.3	1.3	1	0.7	0.7	0.7	0.7
balance-sheet.row.other-non-current-assets	137.2	298.4	394.3	311.5	44.2	13.3	13.4	0.7	1.2	1	0	0.6	0.3	0	0.4
balance-sheet.row.total-non-current-assets	992.3	720.7	590.5	433.8	378.2	276.2	191.8	157.7	127.2	84.4	68.9	56.3	52.2	52.6	45.9
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	2562.2	2197.9	1932	1604.8	1428.2	1057.9	848.3	696.9	611.5	531.3	264	191.1	147.2	110.5	121.4
balance-sheet.row.account-payables	8	7.7	5.1	5.7	8.7	3.4	1.4	1	0.6	1	0.6	0.6	0.6	0.7	4.6
balance-sheet.row.short-term-debt	41.2	4	5.9	5.1	-0.2	0	0	0	0	0	0	0	10	10	0
balance-sheet.row.tax-payables	14.5	30.3	62.9	13	13.2	25.1	16.7	3.9	4.8	7.9	4.7	4.8	4	2.5	0.3
balance-sheet.row.long-term-debt-total	21.3	12.3	1.9	4.7	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Non Current	30.9	27.4	24.9	20.6	16.1	4.9	4.9	4.9	3.9	1.6	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	127.5	91.1	96.6	44.2	51.3	54.2	40.8	35.4	24	15.2	11.4	7.3	0	0	0.5
balance-sheet.row.total-non-current-liabilities	81.4	68	27.4	21.2	16.2	4.9	4.9	4.9	3.9	1.6	0.9	1.8	2.7	3.5	4.4
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	-0.9	0	0	0	0
balance-sheet.row.capital-lease-obligations	21.3	12.3	1.9	4.7	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	258.5	170.8	135.4	76.6	76.3	62.5	47.1	41.3	28.6	17.8	12	9.7	19.6	20.1	9.5
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	523.6	523.6	523.6	523.6	523.6	290.9	161.6	161.6	161.6	161.6	90	90	90	87	126.8
balance-sheet.row.retained-earnings	1262.6	1092.7	889.6	647.5	494.3	532.6	388.3	261.4	201.7	144.1	145.4	81.9	33.5	3.1	-15
balance-sheet.row.accumulated-other-comprehensive-income-loss	270.7	235.1	194.7	156.6	124.9	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	128.2	128.2	128.2	128.2	128.2	146.1	251.4	232.6	219.6	207.8	16.5	9.4	4	0.4	0
balance-sheet.row.total-stockholders-equity	2185.1	1979.6	1736.1	1455.9	1271	969.5	801.3	655.6	582.9	513.6	251.9	181.4	127.6	90.4	111.9
balance-sheet.row.total-liabilities-and-stockholders-equity	2562.2	2197.9	1932	1604.8	1428.2	1057.9	848.3	696.9	611.5	531.3	264	191.1	147.2	110.5	121.4
balance-sheet.row.minority-interest	118.6	47.5	60.5	72.2	81	25.9	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	2303.7	2027.1	1796.6	1528.1	1352	995.4	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	74.2	78.4	83.3	13.9	13.1	13	13	0	0	0	0	0	0	0	0.4
balance-sheet.row.total-debt	62.4	16.3	7.8	9.8	0	0	0	0	0	0	0	0	10	10	0
balance-sheet.row.net-debt	-1108.9	-824.4	-642.2	-573.9	-750.8	-460	-185.8	-235.5	-271.8	-275.5	-103.3	-64.1	-32	-17.4	-43.5

Rahavoogude aruanne

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010
cash-flows.row.net-income	295.5	335.7	326.3	269.7	292.6	231.9	186.1	129.2	117.8	99.5	70.6	53.8	37.3	18.4	10.5
cash-flows.row.depreciation-and-amortization	38.5	26.1	25.1	15	10.4	7.3	6.2	5.7	4.2	3.9	3.6	3.3	3.2	2.6	2.2
cash-flows.row.deferred-income-tax	0	0.5	-1	-0.8	-1.7	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	-0.5	1	0.8	1.7	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	47.4	-47.2	11.5	-26.4	-69.5	-26.2	-28.1	-15.5	-7.4	-19.8	-16.9	-17.2	-22.7	-6.4	1.7
cash-flows.row.account-receivables	0	-30.9	-34.6	-12.2	-53	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-9.4	4.1	-5.4	-11.5	-13.3	-3.6	-5.8	-4.9	2.8	-3.9	-2.9	-0.4	-1	0.2	-0.5
cash-flows.row.account-payables	0	-20.9	52.5	-1.9	-1.5	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	56.8	0.5	-1	-0.8	-1.7	-22.5	-22.3	-10.7	-10.2	-15.9	-14	-16.8	-21.7	-6.5	2.3
cash-flows.row.other-non-cash-items	0.7	45.7	-2.3	-2.2	-0.5	-6.5	-5.1	3.4	0.3	0.1	1.1	1.3	1.4	-0.1	-1.8
cash-flows.row.net-cash-provided-by-operating-activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-209.2	-188.7	-122.2	-70.2	-99.8	-57.8	-34.7	-35.9	-31.5	-22.7	-17.5	-7.2	-4	-10.6	-21.5
cash-flows.row.acquisitions-net	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	21.5
cash-flows.row.purchases-of-investments	-600.1	-484.4	-843.1	-363	-847	-561	-999	-496	-140	-180	0	0	0	0	-0.5
cash-flows.row.sales-maturities-of-investments	612.2	517.6	742.7	337.4	328.1	753.3	865.2	428.4	101.5	121.2	0	0	0	9.8	47.3
cash-flows.row.other-investing-activites	5.1	37.1	10.2	5	11.8	-2.1	0.1	0.9	-0.1	2.6	2	0	0	0	-21.5
cash-flows.row.net-cash-used-for-investing-activites	-191.9	-118.2	-212.3	-90.7	-606.9	132.4	-168.4	-102.6	-70	-78.8	-15.5	-7.2	-4	-0.7	25.4
cash-flows.row.debt-repayment	-20	-5.8	-5.8	0	0	0	0	0	0	0	0	-10	-10	0	0
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-105.6	-105.2	-83.8	-94.2	-72.7	-64.6	-40.4	-56.6	-48.5	-30.3	0	-0.3	-0.5	0	0
cash-flows.row.other-financing-activites	77.2	0	0	0	136.5	0	0	0	0	197.5	-3.5	-1.5	10	-29.9	-27.4
cash-flows.row.net-cash-used-provided-by-financing-activities	-23.4	-111	-89.6	-94.2	63.8	-64.6	-40.4	-56.6	-48.5	167.2	-3.5	-11.9	-0.5	-29.9	-27.4
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	166.8	131.1	58.7	71.2	-310.2	274.2	-49.7	-36.3	-3.7	172.1	39.3	22.1	14.6	-16.1	10.6
cash-flows.row.cash-at-end-of-period	577.6	410.8	279.7	221	149.8	460	185.8	235.5	271.8	275.5	103.3	64.1	42	27.4	43.5
cash-flows.row.cash-at-beginning-of-period	410.8	279.7	221	149.8	460	185.8	235.5	271.8	275.5	103.3	64.1	42	27.4	43.5	32.9
cash-flows.row.operating-cash-flow	382.1	360.3	360.6	256.2	232.9	206.5	159.1	122.8	114.8	83.7	58.3	41.2	19.1	14.5	12.6
cash-flows.row.capital-expenditure	-209.2	-188.7	-122.2	-70.2	-99.8	-57.8	-34.7	-35.9	-31.5	-22.7	-17.5	-7.2	-4	-10.6	-21.5
cash-flows.row.free-cash-flow	172.9	171.5	238.4	186.1	133.1	148.7	124.4	86.8	83.3	61	40.8	33.9	15.2	4	-8.9

Kasumiaruande rida

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga NaN%. 300357.SZ brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010
income-statement-row.row.total-revenue	848.2	896	807.7	636.2	639.4	500.7	385.6	312.1	267.1	239.5	193.6	147.5	103.2	59.3	37.4
income-statement-row.row.cost-of-revenue	40.2	41.3	34.4	28.5	22.9	28.5	14.1	11.6	13.1	9.7	7.4	7.6	6.5	5.7	4.5
income-statement-row.row.gross-profit	808	854.7	773.3	607.7	616.5	472.2	371.5	300.5	254	229.8	186.2	140	96.7	53.6	32.9
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	1	16.1	28.5	16.9	25.2	1.6	2.7	0.4	4.5	6.5	1.5	3	2.8	2.1	0
income-statement-row.row.operating-expenses	494.2	439.5	407.2	313	298.2	218.6	164.5	150.5	125.3	122	104.4	78.8	54.3	35.7	25.9
income-statement-row.row.cost-and-expenses	534.4	480.8	441.6	341.5	321	247.2	178.5	162.1	138.4	131.7	111.8	86.3	60.8	41.4	30.5
income-statement-row.row.interest-income	31	24.8	22.6	23.3	24.2	11.3	3.9	4.5	5.3	4.5	0.9	0.5	0.3	0.7	0
income-statement-row.row.interest-expense	1.3	0.4	0.4	0.1	0.1	11.2	3.8	4.4	0	0	0	0.3	0.5	0	-1
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	1	2.5	0.1	1.1	2.3	19.4	11.9	1.8	9.9	11.1	1.3	2.2	1.6	2.8	2.9
income-statement-row.row.ebitda-ratio-caps	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	1	16.1	28.5	16.9	25.2	1.6	2.7	0.4	4.5	6.5	1.5	3	2.8	2.1	0
income-statement-row.row.total-operating-expenses	1	2.5	0.1	1.1	2.3	19.4	11.9	1.8	9.9	11.1	1.3	2.2	1.6	2.8	2.9
income-statement-row.row.interest-expense	1.3	0.4	0.4	0.1	0.1	11.2	3.8	4.4	0	0	0	0.3	0.5	0	-1
income-statement-row.row.depreciation-and-amortization	38.5	75.9	27.2	-14.1	-13.7	7.3	6.2	5.7	4.2	3.9	3.6	3.3	3.2	2.6	2.2
income-statement-row.row.ebitda-caps	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	345	396.2	392.9	321.5	343.4	271.4	216.2	156	134.1	112.4	81.7	60.4	41.2	18.6	9.8
income-statement-row.row.income-before-tax	346	398.7	393	322.6	345.7	273	219	151.8	138.6	118.9	83.1	63.4	43.9	20.7	9.8
income-statement-row.row.income-tax-expense	50.4	63	66.7	52.9	53.1	41.1	32.9	22.6	20.8	19.3	12.6	9.6	6.7	2.3	-0.7
income-statement-row.row.net-income	310.2	348.8	338	278.4	298.3	232.9	186.1	129.2	117.8	99.6	70.6	53.8	37.3	18.4	10.5